pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1179 |
Genomic Coordinates | chr15: 88608107 - 88608197 |
Synonyms | MIRN1179, hsa-mir-1179, MIR1179 |
Description | Homo sapiens miR-1179 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1179 | ||||||||||||||||||
Sequence | 15| AAGCAUUCUUUCAUUGGUUGG |35 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ARHGAP39 | ||||||||||||||||||||
Synonyms | CrGAP, Vilse | ||||||||||||||||||||
Description | Rho GTPase activating protein 39 | ||||||||||||||||||||
Transcript | NM_025251 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ARHGAP39 | |||||||||||||||||||||
3'UTR of ARHGAP39 (miRNA target sites are highlighted) |
>ARHGAP39|NM_025251|3'UTR 1 CGGGGGCGCCCGGGGACAGGAGGGATGTCCTGCCGCCCCCAGCCAGGCCGAACTCCGCACTCGCTCTCCCGGCAGAGGGG 81 CCAGAATCGCCCGGCCCAGCCCTGGAGCCCCCTCCACTCCCCCAGGCCCCTGGCCCCGGCGCTCCCCACGTCTTCTGCCT 161 GGTCTGAGGGTGCAGCCAGGGCACAGCAGCGGCGGGGAGGGCGCCTCTGGCCCCCCACCTCACGGCCAGTTCCCGCGGGC 241 ACCGCCTCGCCCTCCGCTGGCCGCGGGTCAGCTCCGAGAAAGTGCCTTCTGTGTCCTGGAGCCGAGCGACGCTGCCTCCT 321 TGGGGCCGGGCTGCCTCCCTGTGGCTCCTGCGCGCCCTGGCCTGGGCCTTGCCCAGCCGCCCCGGTCTCTCCTTCCCTTT 401 CTCCTGTCCTCGTCCTGGCCTGCAGCTCTTCCCAGCCCCGAGAGAGCTTCCCGACCTGTCCCCGCCTCCTCTCCCTCCCT 481 CGGCCCGTGGTCCCCAGCTGGTGACTGCTCAGGAGTTTGGGGGCTCCAGGACAGTGGGCCCGGGGCCTGGCAGGCTCTCG 561 GTGGGTGGGGTGGGGGCCCCCAAACCAAAGTCCTCTGGGGTAGGGAGCAGGGCTGGGCAGGCATTCTGGGGGCAGGGTGG 641 GGGAGGGGCGAGAGTATTTTTTTCTTCGTGTAACTGTAAATCCAGAATCTATCCTGCATCGCAGCCCACCGTGTATAGAG 721 ATATAAATAGAGGGAAAGATATAAGAACTAAATTTGCTAATGACATAGTTTTAACCTAAATGCTATTTATCTCTGAGCCG 801 TCCCCGTCCTCCGTGCAGAGCAAGTTGAGGTCATTCCTTCTTTTCTTCTCCGATCTTTTTTCTTGGCTTCTGACCAAAAA 881 CCAAGCTCTACCCCATCCCCATCCCAGACCTGCAGGAGACGAGCGAGCGGGAAGGCGCCGGGCCCGGGACTGTCCGTTCT 961 CGGGGCCAGAGCTGCTGGGGGACCGAGTTTGTACATTTTCCATTTTGGAATTTTGAGTTCCAATTGTTGTAAAACTTAAT 1041 TTCTCCCCAGTTTTTATATATATATTTTTTAGAGTTCCGTTTTTATTTATTAAAAACAAAAGCCCCAGCCCTGCCGAGGC 1121 CTGGGCGGCGTCCTCAGTCGGGTGGTCCCGGGGCCTTTGCGGTCCCGCCCGGCTGAGACGCTCGCCCCGACGCATGGACC 1201 CGAGAGGCGACGACACGAGTGAATAAAGTGCACATGGACCCTGAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | TZM-bl |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
CLIP-seq Support 1 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000377307.2 | 3UTR | CUAUUUAUCUCUGAGCCGUCCCCG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
56 hsa-miR-1179 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT055796 | PLEKHA1 | pleckstrin homology domain containing A1 | 2 | 2 | ||||||||
MIRT165931 | CREBRF | CREB3 regulatory factor | 2 | 2 | ||||||||
MIRT193416 | RORA | RAR related orphan receptor A | 2 | 4 | ||||||||
MIRT270559 | SETD1B | SET domain containing 1B | 2 | 2 | ||||||||
MIRT379031 | CDK6 | cyclin dependent kinase 6 | 2 | 2 | ||||||||
MIRT397265 | WEE1 | WEE1 G2 checkpoint kinase | 2 | 2 | ||||||||
MIRT397728 | PAWR | pro-apoptotic WT1 regulator | 2 | 4 | ||||||||
MIRT442893 | MYNN | myoneurin | 2 | 2 | ||||||||
MIRT443223 | ARL5B | ADP ribosylation factor like GTPase 5B | 2 | 2 | ||||||||
MIRT455068 | ARHGAP39 | Rho GTPase activating protein 39 | 2 | 2 | ||||||||
MIRT457420 | CASC5 | kinetochore scaffold 1 | 2 | 2 | ||||||||
MIRT459303 | PHYKPL | 5-phosphohydroxy-L-lysine phospho-lyase | 2 | 2 | ||||||||
MIRT474139 | LIN54 | lin-54 DREAM MuvB core complex component | 2 | 4 | ||||||||
MIRT480804 | BLOC1S2 | biogenesis of lysosomal organelles complex 1 subunit 2 | 2 | 6 | ||||||||
MIRT483224 | ZWINT | ZW10 interacting kinetochore protein | 2 | 2 | ||||||||
MIRT494968 | USP46 | ubiquitin specific peptidase 46 | 2 | 2 | ||||||||
MIRT496531 | ID2 | inhibitor of DNA binding 2, HLH protein | 2 | 2 | ||||||||
MIRT497593 | SLC23A1 | solute carrier family 23 member 1 | 2 | 2 | ||||||||
MIRT500683 | TRIM37 | tripartite motif containing 37 | 2 | 2 | ||||||||
MIRT506538 | MORF4L1 | mortality factor 4 like 1 | 2 | 4 | ||||||||
MIRT514699 | SOD2 | superoxide dismutase 2 | 2 | 2 | ||||||||
MIRT516421 | ADAMTS4 | ADAM metallopeptidase with thrombospondin type 1 motif 4 | 2 | 2 | ||||||||
MIRT516864 | TYW5 | tRNA-yW synthesizing protein 5 | 2 | 2 | ||||||||
MIRT521048 | SLC2A3 | solute carrier family 2 member 3 | 2 | 4 | ||||||||
MIRT523817 | FAM179A | TOG array regulator of axonemal microtubules 2 | 2 | 4 | ||||||||
MIRT528884 | ATF3 | activating transcription factor 3 | 2 | 2 | ||||||||
MIRT530375 | PCSK1 | proprotein convertase subtilisin/kexin type 1 | 2 | 2 | ||||||||
MIRT536813 | HNRNPA1 | heterogeneous nuclear ribonucleoprotein A1 | 2 | 2 | ||||||||
MIRT537030 | GRIN2B | glutamate ionotropic receptor NMDA type subunit 2B | 2 | 2 | ||||||||
MIRT537864 | EFNA5 | ephrin A5 | 2 | 2 | ||||||||
MIRT544600 | FOXO3 | forkhead box O3 | 2 | 4 | ||||||||
MIRT547016 | PPP1R12A | protein phosphatase 1 regulatory subunit 12A | 2 | 4 | ||||||||
MIRT551016 | DMPK | DM1 protein kinase | 2 | 9 | ||||||||
MIRT551306 | MARVELD2 | MARVEL domain containing 2 | 2 | 2 | ||||||||
MIRT556932 | IREB2 | iron responsive element binding protein 2 | 2 | 2 | ||||||||
MIRT562241 | HMGB1 | high mobility group box 1 | 5 | 2 | ||||||||
MIRT566610 | NR3C1 | nuclear receptor subfamily 3 group C member 1 | 2 | 2 | ||||||||
MIRT567498 | FOXJ3 | forkhead box J3 | 2 | 2 | ||||||||
MIRT573432 | ALDOA | aldolase, fructose-bisphosphate A | 2 | 2 | ||||||||
MIRT575921 | Dmpk | dystrophia myotonica-protein kinase | 2 | 6 | ||||||||
MIRT621349 | AADAC | arylacetamide deacetylase | 2 | 2 | ||||||||
MIRT623719 | HACE1 | HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 | 2 | 2 | ||||||||
MIRT628303 | CREB5 | cAMP responsive element binding protein 5 | 2 | 2 | ||||||||
MIRT629775 | FAM57A | family with sequence similarity 57 member A | 2 | 2 | ||||||||
MIRT668030 | GXYLT2 | glucoside xylosyltransferase 2 | 2 | 2 | ||||||||
MIRT668681 | DPH3 | diphthamide biosynthesis 3 | 2 | 2 | ||||||||
MIRT674268 | ZNF284 | zinc finger protein 284 | 2 | 2 | ||||||||
MIRT681490 | DIP2A | disco interacting protein 2 homolog A | 2 | 2 | ||||||||
MIRT699899 | RUNX1 | runt related transcription factor 1 | 2 | 2 | ||||||||
MIRT700856 | PERP | PERP, TP53 apoptosis effector | 2 | 2 | ||||||||
MIRT701079 | PARD6B | par-6 family cell polarity regulator beta | 2 | 2 | ||||||||
MIRT701503 | NEGR1 | neuronal growth regulator 1 | 2 | 2 | ||||||||
MIRT719117 | MAML1 | mastermind like transcriptional coactivator 1 | 2 | 2 | ||||||||
MIRT720375 | NUDT3 | nudix hydrolase 3 | 2 | 2 | ||||||||
MIRT723639 | STK25 | serine/threonine kinase 25 | 2 | 2 | ||||||||
MIRT737393 | FOXM1 | forkhead box M1 | 4 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|